HII Welcomes High School Seniors to Shipbuilding Careers at Newport News Shipbuilding NEWPORT NEWS, Va., May 09, 2025 (GLOBE NEWSWIRE) -- More than two dozen high school seniors know what they’ll be doing after graduation this year, after accepting offers to begin their shipbuilding careers at HII’s (NYSE: HII) Newport News Shipbuilding division. The shipyard participated in the (NHREC) Good Life Solution Program’s Career Selection Day Thursday, in Hampton. During the event, 18 students accepted employment offers from NNS, to either begin full-time trade positions within the shipyard or...
A director at Huntington Ingalls Industries Inc sold 1,300 shares at 231.910USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
A director at Verona Pharma sold/sold after exercising options 14,373 shares at 70.573USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”),...
Freshpet, Inc. Reports First Quarter 2025 Financial Results Delivers Approximately 18% Net Sales GrowthStrong Operating Performance on Input, Quality and Logistics CostsUpdates 2025 Outlook BEDMINSTER, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Compared to Prior Year Period Net sales of $263.2 million, an increase of 17.6%.Net loss of $12.7 million, compared to the prior year period net income of $18.6 million.Gross...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.